Özlem Anak

6.9k total citations · 1 hit paper
25 papers, 2.0k citations indexed

About

Özlem Anak is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Özlem Anak has authored 25 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Özlem Anak's work include CAR-T cell therapy research (5 papers), Acute Myeloid Leukemia Research (4 papers) and Renal cell carcinoma treatment (4 papers). Özlem Anak is often cited by papers focused on CAR-T cell therapy research (5 papers), Acute Myeloid Leukemia Research (4 papers) and Renal cell carcinoma treatment (4 papers). Özlem Anak collaborates with scholars based in Switzerland, France and United States. Özlem Anak's co-authors include Stephen J. Schuster, Sunita D. Nasta, Bruce L. Levine, Jennifer L. Brogdon, Daniel J. Landsburg, Vijay Bhoj, Mariusz A. Wasik, Simon F. Lacey, J. Joseph Melenhorst and Elise A. Chong and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Özlem Anak

24 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

2017 1.3k citations Stephen J. Schuster, Jakub Svoboda et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Özlem Anak Switzerland	12	1.6k	521	357	347	341	25	2.0k
Lynn Navale United States	17	1.7k 1.0×	387 0.7×	112 0.3×	197 0.6×	317 0.9×	59	2.1k
Leonid Cherkassky United States	12	1.6k 1.0×	588 1.1×	507 1.4×	404 1.2×	762 2.2×	22	2.1k
Andras Heczey United States	19	1.5k 0.9×	527 1.0×	322 0.9×	378 1.1×	898 2.6×	49	2.1k
Jonathan Villena‐Vargas United States	14	1.6k 1.0×	394 0.8×	446 1.2×	364 1.0×	622 1.8×	39	2.1k
Mio Kitano United States	11	1.9k 1.2×	599 1.1×	646 1.8×	600 1.7×	797 2.3×	21	2.4k
Qunrui Ye United States	15	1.4k 0.9×	445 0.9×	303 0.8×	334 1.0×	1.0k 3.0×	17	2.0k
Yukimi Sakoda Japan	17	1.2k 0.8×	361 0.7×	389 1.1×	269 0.8×	898 2.6×	27	1.7k
Saad S. Kenderian United States	25	2.1k 1.3×	737 1.4×	537 1.5×	647 1.9×	790 2.3×	149	2.9k
Timothy S. Fenske United States	27	1.7k 1.0×	435 0.8×	192 0.5×	208 0.6×	522 1.5×	162	2.6k
Marcel Bundi Switzerland	7	602 0.4×	317 0.6×	169 0.5×	141 0.4×	118 0.3×	7	1.2k

Countries citing papers authored by Özlem Anak

Since Specialization

Citations

This map shows the geographic impact of Özlem Anak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Özlem Anak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Özlem Anak more than expected).

Fields of papers citing papers by Özlem Anak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Özlem Anak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Özlem Anak. The network helps show where Özlem Anak may publish in the future.

Co-authorship network of co-authors of Özlem Anak

This figure shows the co-authorship network connecting the top 25 collaborators of Özlem Anak. A scholar is included among the top collaborators of Özlem Anak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Özlem Anak. Özlem Anak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bishop, Michael, Richard T. Maziarz, Edmund K. Waller, et al.. (2019). Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Advances. 3(14). 2230–2236. 57 indexed citations

Awasthi, Rakesh, Constantine S. Tam, Ulrich Jaeger, et al.. (2018). Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Clinical Trials. 78(13).

Awasthi, Rakesh, Constantine S. Tam, Ulrich Jaeger, et al.. (2018). Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Cancer Research. 78(13_Supplement). CT110–CT110. 2 indexed citations

Schuster, Stephen J., Jakub Svoboda, Elise A. Chong, et al.. (2017). Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. New England Journal of Medicine. 377(26). 2545–2554. 1266 indexed citations breakdown →

Zhu, Andrew X., Masatoshi Kudo, Eric Assénat, et al.. (2014). EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. Journal of Clinical Oncology. 32(3_suppl). 172–172. 33 indexed citations

Ravaud, Alain, Carlos H. Barrios, B. Yа. Alekseev, et al.. (2013). Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon α-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results.. Journal of Clinical Oncology. 31(15_suppl). 4576–4576. 7 indexed citations

Motzer, Robert J., Carlos H. Barrios, Tae Min Kim, et al.. (2013). Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 31(15_suppl). 4504–4504. 54 indexed citations

Lebwohl, David, Özlem Anak, Tarek Sahmoud, et al.. (2013). Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Annals of the New York Academy of Sciences. 1291(1). 14–32. 68 indexed citations

Bracarda, Sergio, Thomas E. Hutson, Camillo Porta, et al.. (2012). Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. British Journal of Cancer. 106(9). 1475–1480. 17 indexed citations

10.

Sellami, Dalila, et al.. (2012). Meta-analysis on the relationship between everolimus exposure and safety and efficacy.. Journal of Clinical Oncology. 30(15_suppl). 3099–3099. 1 indexed citations

11.

Finn, Richard S., Thomas Yau, Yibin Kang, et al.. (2011). Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 29(15_suppl). 4074–4074. 17 indexed citations

12.

Köhne, Claus Henning, Eric Van Cutsem, J. Wils, et al.. (2005). Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. Journal of Clinical Oncology. 23(22). 4856–4865. 262 indexed citations

13.

Ducreux, Michel, Eric Van Cutsem, Jean‐Luc Van Laethem, et al.. (2005). A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. European Journal of Cancer. 41(3). 398–403. 96 indexed citations

14.

Suciu, Stefan, G. Verhoef, Boris Labar, et al.. (2003). The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia. 17(5). 859–868. 31 indexed citations

15.

Witte, T. de, JP Marie, Stefan Suciu, & Özlem Anak. (2002). Highlights and strategies of the EORTC Leukemia Group. European Journal of Cancer. 38. 94–99. 1 indexed citations

16.

Anak, Özlem, Eric Van Cutsem, & Bernard Nordlinger. (2002). The EORTC Gastrointestinal Tract Cancer Group. European Journal of Cancer. 38. 65–70. 2 indexed citations

17.

Witte, T de, Stefan Suciu, Michel Delforge, et al.. (2001). Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups. Blood. 98(11). 1 indexed citations

18.

Anak, Özlem, Marie-Hélène Giroix, Abdullah Sener, & Willy Malaisse. (1993). FAD-glycerophosphate dehydrogenase activity in splenocytes of rats with acquired or inherited diabetes mellitus. Medical science research. 21(15). 565–566. 1 indexed citations

19.

Anak, Özlem, et al.. (1993). FAD-Linked Glycerophosphate Dehydrogenase Activity in Islets, Liver, and Splenocytes of NOD Mice. Biochemical Medicine and Metabolic Biology. 50(1). 67–74. 4 indexed citations

20.

Sener, Abdullah, et al.. (1992). High activity of FAD-linked glycerophosphate dehydrogenase in pancreatic islets of diabetic golden spiny mice. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 21(1). 11–17. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact